Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:51 AM ET 8-K
Clinical Trial Data Xencor Inc XNCR

Xencor Clinical Trial Data

Xencor announced updated Phase 1 clinical trial results for XmAb819, an ENPP3 x CD3 bispecific T-cell engager, in patients with advanced clear cell renal cell carcinoma (ccRCC). The company also provided a cash runway update, expecting current resources to fund operations into 2029, and plans to start a potential registration-enabling study for XmAb819 in 2027.

7:51 AM ET 8-K
Capital Raise Strive, Inc. ASST

Strive Capital Raise

Strive, Inc. entered into a sales agreement to establish an at-the-market (ATM) offering program for up to $1.0 billion of its 15.00% Series A Perpetual SATS Preferred Stock. The company intends to use the proceeds for general corporate purposes, including the acquisition of bitcoin and bitcoin-related products, working capital, and potential share repurchases.

Counterparty
Cantor Fitzgerald & Co.
7:09 AM ET 8-K
M&A Deal Range Resources Corp RRC

Range Resources M&A Deal with EQT Corporation

Range Resources Corporation has entered into a definitive agreement to be acquired by EQT Corporation in an all-stock transaction, creating a combined natural gas company with a pro forma enterprise value exceeding $50 billion. Range stockholders will receive 0.987 shares of EQT common stock for each Range share, resulting in Range stockholders owning approximately 27% of the combined entity. The merger aims to create the leading vertically integrated natural gas producer in North America with over 30 years of inventory and significant cost synergies.

Counterparty
EQT Corporation

“This transaction brings together two of the highest-quality, longest-duration asset bases in North America and creates a company uniquely positioned for the next era of natural gas. As the lowest-cost natural gas producer in the industry, supported by multiple decades of high-quality inventory, the combined company will offer exceptional resilience through commodity cycles while maintaining significant upside to strengthening natural gas fundamentals.”

Toby Z. Rice, EQT President and CEO

“This combination of two highly successful operators with decades of inventory creates opportunities to build long-term value neither could fully realize independently.”

Dennis L. Degner, President and CEO of Range
7:00 AM ET 8-K
Bankruptcy & Restructuring Getty Images Holdings, Inc. GETYQ

Getty Images Holdings Bankruptcy & Restructuring

Getty Images Holdings and several subsidiaries filed voluntary petitions for Chapter 11 bankruptcy protection in the District of Delaware to implement a prepackaged plan of reorganization. In connection with the filing, the company entered into a $143 million debtor-in-possession (DIP) credit agreement with Cantor Fitzgerald Securities to fund operations during the restructuring process. The DIP facility includes an initial $85 million draw to cover legal costs, working capital, and general corporate purposes.

Counterparty
Cantor Fitzgerald Securities
7:00 AM ET 8-K
Partnership Zeo ScientifiX, Inc. ZEOX

Zeo ScientifiX Partnership with Pluri Inc.

Zeo ScientifiX and Pluri Inc. entered into a definitive strategic agreement to expand their U.S. manufacturing and commercialization platform for regenerative medicine and aesthetics. The transaction involves a share exchange that will result in Pluri owning 50% of ZEO, combining Pluri's 3D cell-expansion technology with ZEO's biologics manufacturing and physician sales network.

Counterparty
Pluri Inc.
6:51 AM ET 8-K
M&A Deal Ovintiv Inc. OVV

Ovintiv Signs $890M M&A Deal with Logan Energy Corp.

Ovintiv Inc. has entered into a definitive agreement to acquire Logan Energy Corp. in an all-cash transaction valued at approximately $890 million (C$1.26 billion), including the assumption of net debt. The acquisition adds approximately 266,000 net acres and 420 net drilling locations in the oil-rich window of the Montney play, increasing Ovintiv's scale and inventory in the region.

Value
$890M
Counterparty
Logan Energy Corp.

“This bolt-on transaction delivers value for our shareholders by adding high margin oil and condensate production and infrastructure, utilizing our operational advantage to drive significant synergies, and adding to our already deep drilling inventory and future growth optionality. The Logan assets have demonstrated leading oil productivity performance and will immediately compete for capital alongside the rest of our portfolio.”

Brendan McCracken, Ovintiv President and CEO
6:40 AM ET 8-K
M&A Deal Vertiv Holdings Co VRT

Vertiv Holdings M&A Deal with King Environmental Services Ltd.

Vertiv Holdings Co. has completed the acquisition of King Environmental Services Ltd. (KES), a Europe-based provider of fluid management and load-testing services for liquid-cooled data centers. The deal expands Vertiv's thermal management capabilities into the EMEA region, building on its previous acquisition of PurgeRite to support high-density and AI-driven computing environments.

Counterparty
King Environmental Services Ltd.

“As computing density increases, the performance of cooling infrastructure depends not only on engineering and system design but on execution in the field. KES builds on the Vertiv fluid management foundation, extending our specialized expertise and disciplined execution into EMEA as customers deploy increasingly complex infrastructure at scale.”

Giordano Albertazzi, Chief Executive Officer of Vertiv
6:24 AM ET 8-K
Clinical Trial Data Climb Bio, Inc. CLYM

Climb Bio Clinical Trial Data

Climb Bio announced initial Phase 2 data from its PrisMN trial evaluating budoprutug in patients with primary membranous nephropathy (pMN), showing a 70% mean reduction in PLA2R antibody levels at Week 12 in the 200 mg cohort. Initial data from the 600 mg cohort indicated deeper B-cell depletion and greater drug exposure, supporting the ongoing evaluation of higher doses. The company also reported a case study in minimal change disease (MCD) where a patient achieved a three-year steroid-free remission following treatment.

6:17 AM ET 8-K
M&A Deal EQT Corp EQT

EQT Signs $50B M&A Deal with Range Resources Corporation

EQT Corporation has entered into a definitive agreement to acquire Range Resources Corporation in an all-stock transaction, creating a combined natural gas company with a pro forma enterprise value of over $50 billion. Range stockholders will receive 0.987 shares of EQT common stock for each share held, resulting in EQT and Range shareholders owning approximately 73% and 27% of the combined company, respectively. The deal aims to create the largest vertically integrated natural gas producer in the U.S. with significant inventory depth and expected annual synergies of $325 million.

Value
$50B
Counterparty
Range Resources Corporation

“This transaction brings together two of the highest-quality, longest-duration asset bases in North America and creates a company uniquely positioned for the next era of natural gas. As the lowest-cost natural gas producer in the industry, supported by multiple decades of high-quality inventory, the combined company will offer exceptional resilience through commodity cycles while maintaining significant upside to strengthening natural gas fundamentals.”

Toby Z. Rice, EQT President and CEO
6:13 AM ET 8-K
M&A Deal Amanat Acquisition Corp. AMAN

Amanat Acquisition Signs $377M M&A Deal with Corxel Pharmaceuticals, Inc.

Amanat Acquisition Corp (AMAN) has entered into a definitive business combination agreement with Corxel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on oral obesity therapies. The transaction is expected to provide approximately $377 million in gross proceeds, including a $300 million PIPE investment from institutional investors. Upon closing, expected in the first half of 2027, the combined company will focus on advancing Corxel's oral GLP-1 receptor agonist, CX11, into Phase 3 clinical trials.

Value
$377M
Counterparty
Corxel Pharmaceuticals, Inc.
6:03 AM ET 8-K
Capital Raise La Rosa Holdings Corp. SRTM

Stratum Holdings Capital Raise

Stratum Holdings Corp. completed an additional closing under a securities purchase agreement with an institutional investor, issuing 200 shares of Series E Convertible Preferred Stock. The transaction generated gross proceeds of $200,000 at a stated value of $1,000 per share. This follows an initial issuance of 200 shares on September 15, 2026.

Counterparty
institutional investor
6:02 AM ET 8-K
Nasdaq/NYSE Compliance Notice Elme Communities ELMES

Elme Communities Nasdaq/NYSE Compliance Notice

The New York Stock Exchange (NYSE) has commenced proceedings to delist Elme Communities' common shares and immediately suspended trading due to abnormally low selling price levels. The company does not intend to appeal the decision as it is already executing a previously approved Plan of Sale and Liquidation. Elme anticipates its shares will begin trading over-the-counter (OTC) under the symbol 'ELMES' on October 26, 2026.

Counterparty
New York Stock Exchange
6:02 AM ET 8-K
Clinical Trial Data ArriVent BioPharma, Inc. AVBP

ArriVent BioPharma Clinical Trial Data

ArriVent BioPharma announced initial Phase 1 data for its CDH17-targeted antibody-drug conjugate ARR-217 in patients with gastrointestinal cancers, reporting a 44.8% objective response rate at the 6mg/kg dose in late-line colorectal cancer patients. The study, conducted in partnership with Lepu Biopharma, showed a manageable safety profile and has advanced into Phase 1b dose optimization with further data expected in 2027.

Counterparty
Lepu Biopharma Co., Ltd.

“These initial results reinforce our confidence in ARR-217 and in CDH17 as a potential therapeutic target for patients with gastrointestinal cancers who face limited treatment options following prior lines of therapy.”

Bing Yao, Ph.D., Chief Executive Officer of ArriVent

“We believe the responses observed in this heavily pretreated patient population, together with a manageable safety profile, provided a strong foundation for advancing ARR-217 into a Phase 1b dose optimization study.”

Bing Yao, Ph.D., Chief Executive Officer of ArriVent
6:02 AM ET 8-K
Clinical Trial Data Eikon Therapeutics, Inc. EIKN

Eikon Therapeutics Clinical Trial Data

Eikon Therapeutics presented updated Phase 1b data from its TeLuRide-005 trial evaluating EIK1001 in combination with pembrolizumab and chemotherapy for advanced NSCLC at the 2026 ESMO Congress. The trial demonstrated a 63.1% objective response rate (ORR) and 89.2% disease control rate (DCR) across the pooled population, with a safety profile supportive of outpatient administration. The squamous cohort specifically showed a 72.4% ORR and 100% DCR with a median duration of response of 12.9 months.

6:01 AM ET 8-K
Capital Raise Cyber Enviro-Tech, Inc. CETI

Cyber Enviro-Tech Capital Raise

Cyber Enviro-Tech, Inc. entered into Amendment No. 2 to its existing Equity Purchase Agreement with Monroe Street Capital Partners, LP, which allows the company to sell up to $30 million of common stock. The amendment modifies the pricing mechanism for 'put notices' to be based on the end-of-day volume-weighted average price (EOD VWAP) rather than the lowest traded price, while maintaining a 15% discount factor. The company also disclosed a prior amendment that reduced the minimum put amount to facilitate easier access to the capital facility.

Counterparty
Monroe Street Capital Partners, LP
6:01 AM ET 8-K
Nasdaq/NYSE Compliance Notice Charlton Aria Acquisition Corp CHAR

Charlton Aria Acquisition Nasdaq/NYSE Compliance Notice

Charlton Aria Acquisition Corp notified Nasdaq that it failed to satisfy audit committee independence requirements due to a compensatory payment made to a firm associated with director Kyoung Tak Kim. The company regained compliance on October 22, 2026, by removing Mr. Kim from the audit committee and appointing Wang Jo Cha as his replacement.

Counterparty
Nasdaq
5:30 PM ET 8-K
Nasdaq/NYSE Compliance Notice Innventure, Inc. INV

Innventure Nasdaq/NYSE Compliance Notice

Innventure, Inc. received a deficiency notice from Nasdaq on October 23, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has until April 21, 2027, to regain compliance by maintaining a $1.00 bid price for at least 10 consecutive business days. If compliance is not met, the company may be eligible for an additional 180-day period if it transfers its listing to the Nasdaq Capital Market.

Counterparty
Nasdaq
Term
180 days
5:27 PM ET 8-K
Clinical Trial Data Climb Bio, Inc. CLYM

Climb Bio Clinical Trial Data

Climb Bio and Mabworks announced additional Phase 1 clinical data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, demonstrating deep and durable APRIL suppression through 12 weeks. The data showed a 33-day half-life and a 70% reduction in Gd-IgA1 at 12 weeks, supporting a potential every-12-week dosing regimen. The company remains on track to report initial Phase 2 data in the first half of 2027 and plans to initiate a global Phase 3 trial in 2027.

Counterparty
Beijing Mabworks Biotech Co., Ltd.
5:24 PM ET 8-K
Capital Raise 22nd Century Group, Inc. XXII

22nd Century Group Capital Raise of $4.7M

22nd Century Group filed a prospectus supplement to sell up to $18.8 million in common stock through an at-the-market (ATM) offering program. The company disclosed that during October 2026, it sold approximately 15.79 million shares, raising gross proceeds of approximately $4.7 million.

Value
$4.7M
Counterparty
Needham & Company, LLC
5:19 PM ET 8-K
Capital Raise Traws Pharma, Inc. TRAW

Traws Pharma Capital Raise

Traws Pharma entered into a common stock purchase agreement with Roth Principal Investments for an equity line of credit of up to $50 million. The company has the right, but not the obligation, to sell shares to Roth over a 36-month period following the effectiveness of a registration statement. This facility provides the company with flexible access to capital to fund operations at its sole discretion.

Counterparty
Roth Principal Investments, LLC
Term
36 months
5:16 PM ET 8-K/A
M&A Deal Proficient Auto Logistics, Inc PAL

Proficient Auto Logistics M&A Deal with Hansen & Adkins Auto Transport, LLC

Proficient Auto Logistics, Inc. (PAL) completed its acquisition of the Hansen & Adkins group of companies, including H&A Auto Transport, H&A Auto Logistics, Royal Truck Leasing, and H&A Canada. This filing serves as an amendment to provide the required audited and pro forma financial statements for the acquired businesses following the closing on August 13, 2026.

Counterparty
Hansen & Adkins Auto Transport, LLC
5:15 PM ET 8-K
Nasdaq/NYSE Compliance Notice Medicus Pharma Ltd. MDCX

Medicus Pharma Nasdaq/NYSE Compliance Notice

Medicus Pharma Ltd. regained compliance with Nasdaq's $1.00 minimum bid price requirement after its common shares closed at or above $1.00 for ten consecutive business days. This compliance notice supersedes a delisting determination letter received on October 20, 2026, which had initially triggered a delisting process due to the company's failure to meet the bid price and stockholders' equity requirements.

Counterparty
Nasdaq
5:11 PM ET 8-K
M&A Deal Silver Bow Mining Corp. SBMT

Silver Bow Mining M&A Deal with Montana Goldfields, Inc. and Montana Tunnels Mining, Inc.

Silver Bow Mining Corp. entered into an amendment to its existing asset purchase agreement with Montana Goldfields and Montana Tunnels Mining to update the deal timeline. The amendment extends the 'Outside Date' for the transaction to 60 days following the delivery of audited financial statements and sets a target date of October 31, 2026, for the sellers to produce those financials.

Counterparty
Montana Goldfields, Inc. and Montana Tunnels Mining, Inc.
5:06 PM ET 8-K
Capital Raise Alpine Income Property Trust, Inc. PINE

Alpine Income Property Trust Capital Raise

Alpine Income Property Trust, Inc. announced a preferred stock offering of 189,747 additional shares of its 8.00% Series A Cumulative Redeemable Preferred Stock. In connection with the offering, the company's manager agreed to waive 50% of the base management fee attributable to the new equity proceeds, reducing the fee rate from 1.50% to 0.75% per annum on that capital.

5:05 PM ET 8-K
M&A Deal Transocean Ltd. RIG

Transocean M&A Deal with Valaris Limited

Transocean Ltd. provided a status update on its pending acquisition of Valaris Limited, announcing that the Bermuda Court sanction hearing is scheduled for November 26, 2026. If sanctioned, the company anticipates the business combination will be consummated on or about December 1, 2026, following shareholder meetings on November 24, 2026.

Counterparty
Valaris Limited
5:02 PM ET 8-K
Clinical Trial Data Cumberland Pharmaceuticals Inc CPIX

Cumberland Pharmaceuticals Clinical Trial Data

Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc clinical trial evaluating oral ifetroban in patients with systemic sclerosis. The study results supported the safety and tolerability of the drug candidate in this rare disease population.

5:01 PM ET 8-K
M&A Deal Valaris Ltd VAL

Valaris M&A Deal with Transocean Ltd.

Valaris Limited provided a status update on its pending merger with Transocean Ltd., announcing that the Bermuda Court sanction hearing is scheduled for November 26, 2026. If the court sanctions the Scheme of Arrangement, the companies anticipate the business combination will be consummated on or about December 1, 2026.

Counterparty
Transocean Ltd.
4:53 PM ET 8-K
Nasdaq/NYSE Compliance Notice ARC Group Securities Acquisition I FJDI

ARC Group Securities Acquisition I Nasdaq/NYSE Compliance Notice

ARC Group Securities Acquisition I received a deficiency notice from Nasdaq because the aggregate market value of its outstanding warrants fell below the $1 million minimum requirement. The company has until December 4, 2026, to submit a plan to regain compliance, which could grant an extension until April 18, 2027. This notice currently only affects the listing of the warrants (FJDIW) and not the company's ordinary shares or units.

Counterparty
Nasdaq
Term
180 days
4:49 PM ET 8-K
M&A Deal Energy Services of America Corp ESOA

Energy Services of America Signs $6.95M M&A Deal with FAMCO, Inc.

Energy Services of America Corporation completed the acquisition of substantially all operating assets of FAMCO, Inc., a West Virginia utility contractor focused on water and sewer infrastructure. The base purchase price was $6.95 million, paid through a combination of cash and Energy Services common stock. The deal expands the company's capabilities and workforce in the water and utility construction markets.

Value
$6.95M
Counterparty
FAMCO, Inc.
4:49 PM ET 8-K
Capacity Expansion Allegiant Travel CO ALGT

Allegiant Travel Capacity Expansion: $720M Investment

Allegiant Travel Company exercised options to purchase six additional Boeing 737-8 aircraft scheduled for delivery in 2028, bringing its total firm orders to 56 aircraft. The list price for the six aircraft exceeds $720 million, though final prices are subject to discounts and escalations. Additionally, the company entered into new multi-year employment agreements with its executive leadership team, including CEO Gregory Anderson and President/CFO Robert Neal.

Value
$720M
Counterparty
The Boeing Company
Term
through 2028

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.